logo
RSV is common and sometimes dangerous. Here's what to know.

RSV is common and sometimes dangerous. Here's what to know.

Yahoo09-05-2025

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related RSV spikes are in the news, the virus is actually just as worrisome in older adults.
In fact, while more than 2 million children under age 5 make an RSV-related outpatient visit each year with some 58,000 to 80,000 of them ending up in the hospital, far more older adults infected with the viral disease are hospitalized, per surveillance data from the U.S. Centers for Disease Control and Prevention. The organization notes that between 100,000 and 150,000 adults age 60 and older end up being hospitalized because of RSV each year.
Here's what RSV is, why it especially impacts the youngest and oldest members of society and how it is usually treated.
RSV is a respiratory virus that infects the nose, throat and lungs. While people with larger airways and strong immune systems aren't as adversely affected by the infection, young children and older adults often are. The main reason infants and toddlers struggle is "due to the size of their airways," says Dr. David Hill, a North Carolina-based pediatrician and a spokesperson of the American Academy of Pediatrics. "RSV clogs up the smallest breathing tubes (known as bronchioles) in the child's lungs – and the smaller the lungs, the more severe the effects." He adds that older adults are similarly affected "due to age-related loss of lung tissue and diminished immune function and chest muscle strength." The same can be said for people with certain lung conditions such as asthma or COPD.
Airway blockage and reduced lung function can diminish a vulnerable person's ability to eat, drink or even breathe, which is why nutrients and fluids may need to be administered intravenously with oxygen assistance often also becoming necessary.
RSV is spread from person to person, with the virus "often hitching a ride on a sneeze, a kiss or a shared toy," says Hill. Once germs are inhaled either directly from expelled respiratory droplets or by touching an infected surface, then touching one's eyes, nose or mouth, it usually takes between four to six days for symptoms to appear.
Noted: Nearly 1 in 10 Americans have asthma. Here's what causes it.
Common RSV symptoms in many people include "a runny nose, cough, sneezing and fever – basically mild cold-like symptoms that are mostly contained to the upper respiratory tract," says Dr. Alison Mitzner, a board-certified pediatrician in New York City and the author of "Calm and Confident Parenting." In this stage, RSV can be hard to distinguish from the common cold or other respiratory viruses like COVID-19 or influenza.
But things change when the virus moves from the upper respiratory system to the lower respiratory tract. Once in the trachea, bronchioles and lungs, "RSV can wreak havoc and cause symptoms like wheezing and difficulty breathing and lead to infections like bronchiolitis or pneumonia," Mitzner says.
In toddlers, some of the earliest signs that RSV has infected the lower respiratory system are a diminished interest in eating and decreased vocalizations such as crying, cooing or speaking, says Hill. "You may also see the skin pulling between their ribs, under their rib cage, or over the collarbones and the base of the neck as they struggle to breathe," he adds. "And you may notice a grunting sound with each breath, the nose flaring when they inhale or the head bobbing up and down with breathing." As oxygen and nutrient intake diminish, energy levels quickly follow and infected children often become sleepy or unresponsive. "Children with any of these symptoms should be seen immediately by a medical provider," advises Hill.
Ditto for older adults or immunocompromised people who have recently had cold-like symptoms and are now struggling to breathe, experiencing dizziness or confusion or are eating/drinking less.
Feeling dizzy? It could be dehydration. Here's what to know.
RSV that has moved from the upper to lower respiratory tract in vulnerable people is often treated in hospital settings with the primary goal being to help with oxygen assistance and nutrient intake until the body kills the virus. Professional care also sometimes includes "airway clearance with the help of respiratory therapists," says Hill. "Albuterol or saline nebulizer treatments are also sometimes recommended, but few patients respond to them."
When RSV symptoms remain mild, symptoms can be treated at home. "Common at-home treatments and remedies include nasal saline with suctioning, using a cool-mist humidifier, frequent fluids and feedings to ensure hydration and taking acetaminophen or ibuprofen (if older than 6 months) for fever," says Mitzner.
For most people, RSV symptoms "tend to peak between days three to five of the illness," she adds, "but may last up to two weeks."
This article originally appeared on USA TODAY: How to treat RSV

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Botox may increase your face value — but you're better off trying this move that doesn't cost a cent, scientists say
Botox may increase your face value — but you're better off trying this move that doesn't cost a cent, scientists say

New York Post

time37 minutes ago

  • New York Post

Botox may increase your face value — but you're better off trying this move that doesn't cost a cent, scientists say

Dolly Parton was right. Botox may increase face value for a growing number of Americans, including celebs like Nicole Kidman and Meghan Trainor — but when it comes to making yourself desirable to a prospective partner, researchers say smiling can be even more effective. New research suggests that the popular cosmetic injections do increase users' curb appeal — but when respondents in a survey were asked to rate an array of strange faces, those with upturned lips beat those who merely plumped them up. 4 The research found that smiling could be more effective at enhancing visual appeal than filler injections (pictured). Stasique – Scientists at Tilburg University in The Netherlands also reported that Botox users were likely to be seen as one-night stand prospects — and that getting the costly jabs weren't necessarily useful to those hoping to be taken more seriously as viable life partners. The illusion-shattering findings, published in the journal 'Perception,' come amid a worldwide uptick in Botox usage. Usage of the injectable 'tweakment' has become so frequent that people are actually developing an immunity. Researchers set out to test if people who undergo Botox and other filler treatments are perceived 'more positively by others,' per study co-author Dr. Bastian Jaeger, who claimed that 'existing research on the effectiveness of these treatments is not very strong.' To see if it's worth literally putting one's money where their mouth is, the scientists followed 114 participants who underwent Botox and dermal filler treatments, the Times Of London reported. 4 Study authors found that while Botox can make you more attractive as a mate, it won't necessarily get you to happily ever after any faster. Vasyl – They then asked around 3,000 people to rate their before and after pics on a 7-point attractiveness scale. After reviewing said snaps, which were shot carefully to keep the lighting, expression and other factors consistent across the pics, participants overwhelmingly found that Botox does indeed boost people's visual appeal. 'This difference was rather small: a 0.07-point change in our 7-point attractiveness scale on average,' explained Dr. Jaeger per the Daily Mail. 'This means that on average, a person who was rated a 4 out of 7 on attractiveness before the treatment might be rated a 4.07 out of 7 after treatment.' 4 Participants were asked to evaluate the before-and-after pics of Botox recipients. Sage Journals There was also an increase of 0.13 with regards to how youthful the participants were thought of. However, this paled in comparison to another, less expensive way of enhancing one's attractiveness: smiling. Researchers found that turning one's frown upside down — and not cosmetically — caused one's so-called hotness to soar by 0.4 points, six times more than Botox. 4 'We did not see any benefits of treatment on how competent, intelligent, charismatic, friendly or trustworthy people were perceived to be,' said Jaeger. Drobot Dean – Meanwhile, applying makeup gave people's perceived looks a boost of 0.6 points compared to the filler treatment, which starts at around $300 for a simple forehead injection and involves obstructing nerve signals to muscles, relaxing them and curbing wrinkles. There was another major caveat to alleged Botox-enhanced hotness. While the aesthetic accelerant increased people's desirability as a short-term fling prospect and as a platonic pal — a rise of 0.09 in both categories — there was no statistical improvement in how they were seen as long-term partners. It's unclear why Botox didn't up people's image as soulmate material, but scientists noted that the jabs had no effect on the perception of character traits either. 'We did not see any benefits of treatment on how competent, intelligent, charismatic, friendly or trustworthy people were perceived to be,' said Jaeger. Interestingly, while small amounts of botox did not significantly enhance physical appeal, many people report that, 'after treatment, they find it easier to make friends and that they make a better impression on others,' per Jaeger. Dr. Jaeger attributed this phenomenon to a placebo effect of sorts. 'It is plausible that people have more success socially, not because they look different and people treat them differently, but because they think they do and act more confidently around others (sort of a self-fulfilling prophecy),' he said.

Post-Traumatic Stress Disorder Epidemiology and Strategic Analysis Highlight Growth Opportunities in PTSD Market
Post-Traumatic Stress Disorder Epidemiology and Strategic Analysis Highlight Growth Opportunities in PTSD Market

Yahoo

time38 minutes ago

  • Yahoo

Post-Traumatic Stress Disorder Epidemiology and Strategic Analysis Highlight Growth Opportunities in PTSD Market

Explore the booming PTSD therapeutics market, projected to grow from $1.2 billion in 2024 to $5.4 billion by 2034 at a 15.8% CAGR. Key drivers include new pipeline products and psychedelic therapeutics. Discover market insights, competitor analysis, and strategic opportunities in the 7MM market. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Post-Traumatic Stress Disorder: Opportunity Assessment and Forecast" report has been added to report covers the 7MM and provides an Excel-based forecast model for the Post-Traumatic Stress Disorder market through psychotherapy is widely considered to be the first line of therapeutic intervention for PTSD patients, with pharmacotherapy often used as an adjunct to psychotherapy. Only two drugs, both SSRIs, have been approved by the FDA for the treatment of PTSD: Zoloft (sertraline) and Paxil (paroxetine). The central issue with pharmacotherapy in PTSD is a lack of efficacy of available treatments. The PTSD market across the 7MM was valued at $1.2 billion in the 2024 baseline year and is projected to grow at a compound annual growth rate (CAGR) of 15.8%, reaching $5.4 billion by 2034. A key driver of growth will be the launch of eight late-stage pipeline products, including the first psychedelic therapeutics for Scope Overview of Post-Traumatic Stress Disorder (PTSD), including epidemiology, symptoms, diagnosis, and disease management. Annualized PTSD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PTSD market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PTSD. The most promising candidates in late-stage development are profiled. Analysis of the current and future market competition in the 7MM PTSD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the 7MM PTSD therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the PTSD therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Company Coverage: GSK Eli Lilly and Co Otsuka Pharmaceutical Co Ltd Pfizer Seelos Therapeutics Ananda Scientific Lykos Therapeutics Idorsia Pharmaceutical Compass Pathways Transcend Therapeutics Neuphoria Therapeutics Key Topics Covered: 1. Preface2. Executive Summary3. Disease Overview3.1. Overview of PTSD3.2. Pathophysiology of PTSD3.3. Classification of PTSD3.4. PTSD SWOT Analysis4. Epidemiology4.1. 12-Month Total Prevalent Cases of PTSD, Men and Women, Ages ? 18 Years, 2024?344.2. Age-Specific 12-Month Total Prevalent Cases of PTSD, Men and Women, 20244.3. Sex-Specific 12-Month Total Prevalent Cases of PTSD, Ages ?18 Years, 20244.4. 12-Month Total Prevalent Cases of PTSD by Disease Status, Men and Women, Ages ?18 Years, 20244.5. Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD4.6. Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD by Disease Status4.7. Sources Used to Forecast the 12Month Total Prevalent Cases of PTSD by Military Status4.8. Sources and Methodology - 12-Month Total Prevalent Cases of PTSD4.9. Sources and Methodology - 12-Month Total Prevalent Cases of PTSD by Disease Status5. Current Treatment Options5.1. Treatment Paradigm5.2. Current Treatment Options5.3. Product Profile: Pfizer's Zoloft/Besitran/Lustral (sertraline)5.4. Product Profile: GSK's Paxil/Deroxat/Seroxat/Aropax (paroxetine)5.5. Product Profile: Eli Lilly's Prozac (fluoxetine)5.6. Product Profile: Pfizer's Effexor XR/Effexor/Effexor XL/Vandral (venlafaxine)5.7. Product Profile: Pfizer's Minipress/Hypovase (prazosin)5.8. Patient Flow: PTSD in 2024 Across 7MM6. Unmet Needs and Opportunities6.1. Unmet Needs in PTSD6.2. New Therapeutic Options with Improved Efficacy6.3. Increase Access to Psychotherapy6.4. Treatment Options with Improved Side-Effect Profiles6.5. More consistent diagnostic and treatment guidelines7. R&D Strategies7.1. Trends in Clinical Trial Design in PTSD7.2. Regulatory Challenges for Psychedelic Treatments7.3. Timeline of Regulatory Challenges for Lykos Therapeutics7.4. Trends in Deal-Making in PTSD8. Pipeline Assessment8.1. PTSD Pipeline Overview8.2. Late-Stage Pipeline Agents for PTSD8.3. Product Profile: Otsuka Pharmaceutical's Rexulti (brexpiprazole)8.4. Product Profile: Neuphoria Therapeutics' BNC-2108.5. Product Profile: Idorsia Pharmaceutical's Quviviq (daridorexant)8.6. Product Profile: Ananda Scientific's Nantheia ATL5 (cannabidiol)8.7. Product Profile: Transcend Therapeutics' TSND-201 (methylone)8.8. Product Profile: Lykos Therapeutics' midomafetamine hydrochloride8.9. Product Profile: Seelos Therapeutics' Ereska (ketamine hydrochloride)8.10. Product Profile: Compass Pathways' COMP360 (psilocybin)8.11. PTSD: Clinical Trials (Phase II/III) Overview9. Market Outlook9.1. PTSD Market Forecast9.2. Market Drivers and BarriersFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

California petitions FDA to undo RFK Jr.'s new limits on abortion pill mifepristone
California petitions FDA to undo RFK Jr.'s new limits on abortion pill mifepristone

Los Angeles Times

time41 minutes ago

  • Los Angeles Times

California petitions FDA to undo RFK Jr.'s new limits on abortion pill mifepristone

California and three other states petitioned the U.S. Food and Drug Administration Thursday to ease its new restrictions on the abortion pill mifepristone, citing the drug's proven safety record and arguing the new limits are unnecessary. 'The medication is a lifeline for millions of women who need access to time-sensitive, critical healthcare — especially low-income women and those who live in rural and underserved areas,' said California Atty. Gen. Rob Bonta, who filed the petition alongside the attorneys general of Massachusetts, New York and New Jersey. The petition cites Senate testimony by Health and Human Services Secretary Robert F. Kennedy Jr. last month, in which Kennedy said he had ordered FDA administrator Martin Makary to conduct a 'complete review' of mifepristone and its labeling requirements. The drug, which can be received by mail, has been on the U.S. market for 25 years and taken safely by millions of Americans, according to experts. It is the most common method of terminating a pregnancy in the U.S., with its use surging after the Supreme Court overturned Roe vs. Wade in 2022. The Supreme Court upheld access to the drug for early pregnancies under previous FDA regulations last year, but it has remained a target of anti-abortion conservatives. The Trump administration has given Kennedy broad rein to shake up American medicine under his 'Make America Healthy Again' banner, and Kennedy has swiftly rankled medical experts by using dubious science — and even fake citations — to question vaccine regimens and research and other longstanding public health measures. At the Senate hearing, Kennedy cited 'new data' from a flawed report pushed by anti-abortion groups — and not published in any peer-reviewed journal — to question the safety of mifepristone, calling the report 'alarming.' 'Clearly, it indicates that, at very least, the label should be changed,' Kennedy said. Sen. Josh Hawley (R-Mo.) on Monday posted a letter from Makary to X, in which Makary wrote that he was 'committed to conducting a review of mifepristone' alongside 'the professional career scientists' at the FDA. Makary said he could not provide additional information given ongoing litigation around the drug. The states, in their 54-page petition, wrote that 'no new scientific data has emerged since the FDA's last regulatory actions that would alter the conclusion that mifepristone remains exceptionally safe and effective,' and that studies 'that have frequently been cited to undermine mifepristone's extensive safety record have been widely criticized, retracted, or both.' Democrats have derided Kennedy's efforts to reclassify mifepristone as politically motivated and baseless. 'This is yet another attack on women's reproductive freedom and scientifically-reviewed health care,' Gov. Gavin Newsom said the day after Kennedy's Senate testimony. 'California will continue to protect every person's right to make their own medical decisions and help ensure that Mifepristone is available to those who need it.' Bonta said Thursday that mifepristone's placement under the FDA's Risk Evaluation and Mitigation Strategy program for drugs with known, serious side effects — or REMS — was 'medically unjustified,' unduly burdened patient access and placed 'undue strain on the nation's entire health system.' He said mifepristone 'allows people to get reproductive care as early as possible when it is safest, least expensive, and least invasive,' is 'so safe that it presents lower risks of serious complications than taking Tylenol,' and that its long safety record 'is backed by science and cannot be erased at the whim of the Trump Administration.' The FDA has previously said that fewer than 0.5% of women who take the drug experience 'serious adverse reactions,' and deaths are exceedingly rare. The REMS program requires prescribers to add their names to national and local abortion provider lists, which can be a deterrent for doctors given safety threats, and pharmacies to comply with complex tracking, shipping and reporting requirements, which can be a deterrent to carrying the drug, Bonta said. It also requires patients to sign forms in which they attest to wanting to 'end [their] pregnancy,' which Bonta said can be a deterrent for women using the drug after a miscarriage — one of its common uses — or for those in states pursuing criminal penalties for women seeking certain abortion care. Under federal law, REMS requirements must address a specific risk posed by a drug and cannot be 'unduly burdensome' on patients, and the new application to mifepristone 'fails to meet that standard,' Bonta said. The states' petition is not a lawsuit, but a regulatory request for the FDA to reverse course, the states said. If the FDA will not do so nationwide, the four petitioning states asked that it 'exercise its discretion to not enforce the requirements' in their states, which Bonta's office said already have 'robust state laws that ensure safe prescribing, rigorous informed consent, and professional accountability.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store